A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Clinical trial NCT02961881 · COMPLETED
Trial details
- NCT number
- NCT02961881
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-18
- Primary completion
- 2021-09-02
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.